Respinova has developed a novel non-invasive technology, Pulsehaler, that treats the core of COPD pathophysiology, small airway collapse. COPD is projected to be the world's 3rd leading cause of death by 2020, affecting 5-10% of the population ovedr 40. We are also applying our technology to improve the delivery of inhaled drugs. Both of these solutions have been proven in clinical trials, and we are currently awaiting both FDA clearance and CE mark.
Publié le mardi 27 novembre 2018 14:46
Respinova attended the Innovative Enterprise Vienna conference last week after having been selected from the best Seal of Excellence candidates.
Click to watch our video presentation.
Il n'y a pas encore d'organisations dans le réseau.
